Hammer toe

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Retrieved on: 
Wednesday, September 20, 2023
Deformity, Surgeon, American Orthopaedic Foot and Ankle Society, Social, Annual, NUALS Arts and Literary Annual Meet, MD–MS program, Instrument, Trial of the century, Recurrence, Patient, Manuscript, Hammer toe, MD, Bunion, Poster, HVA, Micro, Dissection, Pharmaceutical industry, Nursing, Medical device, Medical imaging

The Micro-Lapiplasty™ System is currently in limited clinical release with full commercial launch expected in the fourth quarter of this year.

Key Points: 
  • The Micro-Lapiplasty™ System is currently in limited clinical release with full commercial launch expected in the fourth quarter of this year.
  • Additionally, at 36 months post-procedure, less than 5% of patients were unsatisfied with the overall results of the procedure (n=96).
  • The poster, which includes additional details, can be accessed by AOFAS meeting attendees on a kiosk at the Annual Meeting or on the mobile app.
  • The Company plans to submit its primary endpoint ALIGN3D™ manuscript for publication in a top-tier peer-reviewed foot and ankle journal later in 2023.

Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures

Retrieved on: 
Monday, September 11, 2023
American Orthopaedic Foot and Ankle Society, Bunion, Foot, Deformity, Hammer toe, PEEK, Medical device, Treace Medical Concepts

PONTE VEDRA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, is pleased to announce the recent limited market release of several new complementary technologies for treating bunions and bunion-related procedures. These products will be available in limited market release in the U.S. through Treace’s bunion-focused sales team with a full market release expected in the fourth quarter of 2023.

Key Points: 
  • PONTE VEDRA, Fla., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, is pleased to announce the recent limited market release of several new complementary technologies for treating bunions and bunion-related procedures.
  • These products will be available in limited market release in the U.S. through Treace’s bunion-focused sales team with a full market release expected in the fourth quarter of 2023.
  • The Company’s new Hammertoe PEEK Fixation System is designed to address hammertoe, claw toe and mallet toe deformities.
  • “In addition to the large and underpenetrated market for treating bunions, these new technologies are expected to meaningfully expand our addressable market opportunity to include additional procedures that complement our proprietary Lapiplasty® and Adductoplasty® procedures,” said John T. Treace, CEO, Founder and Board Member of Treace.

Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

Retrieved on: 
Thursday, May 19, 2022
Biotechnology, Health, Surgery, Medical Devices, Paragon, Chicken feet, Foot, JAWS, FNA, Surgeon, Multimedia, Bunion, Contracture, Recurrence, Charcot foot, Titanium, Ankle, NYSE, Hammer toe

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac 2.0 Soft Tissue Fixation System.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac 2.0 Soft Tissue Fixation System.
  • The TenoTac 2.0 Soft Tissue Fixation System uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surface.
  • TenoTac 2.0 adds to our growing portfolio of soft tissue products and the Hammertoe segment, with opportunities for significant improvements in patient outcomes.
  • The addition of the TenoTac 2.0 Soft Tissue Fixation System bolsters Paragon 28s hammertoe product offering, which includes the Paratrooper Plantar Plate System, HammerTube Hammertoe System, Mini-Monster Screw System, and JAWS Staple System.

Paragon 28 Launches Paratrooper™ Plantar Plate System for Hammertoe and Soft Tissue Repair

Retrieved on: 
Wednesday, April 27, 2022
Health, Surgery, Other Health, Medical Devices, Paragon, Bunion, Recurrence, Hammer toe, Foot, FNA, Charcot foot, Business, JAWS, Contracture, Surgeon, Plantar plate, Chicken feet, NYSE, Ankle, Multimedia, 3D printing

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammertoe and soft-tissue portfolio with the launch of its Paratrooper Plantar Plate Repair System.

Key Points: 
  • Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its hammertoe and soft-tissue portfolio with the launch of its Paratrooper Plantar Plate Repair System.
  • The Paratrooper Plantar Plate Systems low profile, all-suture implant provides surgeons a new and innovative approach for plantar plate repair and forefoot deformities.
  • View the full release here: https://www.businesswire.com/news/home/20220427005149/en/
    Paratrooper Plantar Plate System (Graphic: Business Wire)
    Paragon 28s CEO, Albert DaCosta, commented, Repair of the plantar plate has historically been one of the more challenging pathologies within the hammertoe sub-segment.
  • The addition of the Paratrooper Plantar Plate System bolsters Paragon 28s hammertoe product offering, which includes the TenoTac Soft Tissue Fixation System, HammerTube Hammertoe System, Mini-Monster Screw System, and JAWS Staple System.

Armis Biopharma Announces FDA Approval of VeriFixx™ Small Bone Implant

Retrieved on: 
Thursday, November 19, 2020
Prosthetics, Medicine, Medical specialties, Surgery, Arthropathies, Hammer toe, Implant

FORT COLLINS, Colo., Nov. 19, 2020 /PRNewswire/ --Armis Biopharma, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the VeriFixx Small Bone Implant for the fixation of osteotomies and reconstruction of the lesser toes following correction procedures for hammertoe, claw toe and mallet toe.

Key Points: 
  • FORT COLLINS, Colo., Nov. 19, 2020 /PRNewswire/ --Armis Biopharma, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the VeriFixx Small Bone Implant for the fixation of osteotomies and reconstruction of the lesser toes following correction procedures for hammertoe, claw toe and mallet toe.
  • VeriFixx is designed to make surgical corrections of this kind more accessible to patients through shorter time to ambulation, shorter overall recovery time and reduced pain.
  • "For patients requiring a small bone implant, the length of recovery and pain are common concerns," said Ted Ziemann, Chairman and CEO of Armis Biopharma.
  • In the U.S., there are approximately 500,000 small bone implant procedures each year.

Hammertoe Surgery Group of NYC is Now Offering Free Virtual & In Person Consultations

Retrieved on: 
Thursday, August 20, 2020
Podiatry, Arthropathies, Hammer toe, Podiatrist, Suzanne Levine, Surgeon, Specialty, Surgery

NEW YORK, Aug. 20, 2020 /PRNewswire-PRWeb/ --Hammertoe Surgery Group of NYC (located on the Upper East Side in Manhattan, NY) announced today that they will be offering complimentary virtual and in-person consultations for hammertoe surgery, bunion surgery, corn surgery, as well as 2nd opinions.

Key Points: 
  • NEW YORK, Aug. 20, 2020 /PRNewswire-PRWeb/ --Hammertoe Surgery Group of NYC (located on the Upper East Side in Manhattan, NY) announced today that they will be offering complimentary virtual and in-person consultations for hammertoe surgery, bunion surgery, corn surgery, as well as 2nd opinions.
  • Dr. Suzanne Levine, director of Hammertoe Surgery Group of NYC stated, "We fully acknowledge that in person foot surgery consultations may not be practical for some of our potential patients during Covid-19.
  • The Hammertoe Surgery Group of NYC is comprised of board-certified experienced podiatrists and foot surgeons who are leaders in the field of podiatry and who have been trained in world-renowned foot surgery training programs.
  • Our foot surgery specialists hold academic and clinical positions at some of the NYCs top universities and hospitals in Manhattan, New York.

Nextremity Solutions, Inc. Receives FDA 510(k) Clearance for Cannulated Hammertoe System

Retrieved on: 
Friday, July 3, 2020
Musculoskeletal system, Arthropathies, Hammer toe, Medical Subject Headings, Toe, Medical classification, SmartToe, Draft:Hammer Toe Orthopedic Surgery

The DuoHex CH System addresses hammertoe deformity in patients and provides surgeons with a novel two-piece threaded implant construct is designed for optimum bone purchase.

Key Points: 
  • The DuoHex CH System addresses hammertoe deformity in patients and provides surgeons with a novel two-piece threaded implant construct is designed for optimum bone purchase.
  • The design of the cannulated implants and instruments provide targeting and technique guidance for repeatable outcomes.
  • Ryan Schlotterback, Chief Technology Officer for Nextremity Solutions said, "Nextremity Solutions was founded years ago by surgeons with a passion for the foot and ankle market and with an innovative solution for hammertoe correction.
  • The Nextremity Solutions DuoHex CH Cannulated Hammertoe System is indicated for small bone reconstruction limited to interphalangeal repair and fusion of the lesser toes.

Pinckney Michigan foot doctor and podiatrist Tomasz Biernacki discusses bunion & hammer toe non-surgery treatment vs. the need for surgery in Livingston County

Retrieved on: 
Monday, June 15, 2020
Musculoskeletal system, Medical specialties, Organ systems, Skeletal disorders, RTT, Foot diseases, Arthropathies, Podiatrist, Podiatry, Hammer toe, Bunion, Flat feet

PINCKNEY, Mich., June 15, 2020 /PRNewswire-PRWeb/ -- Dr. Tomasz Biernacki states that "If bunion, hammer toe and flat foot formation can be caught relatively early, this will prevent permanent arthritis from developing.

Key Points: 
  • PINCKNEY, Mich., June 15, 2020 /PRNewswire-PRWeb/ -- Dr. Tomasz Biernacki states that "If bunion, hammer toe and flat foot formation can be caught relatively early, this will prevent permanent arthritis from developing.
  • Dr. Biernacki further states "It is estimated that the people who develop flat feet and bunion formation can have further knee pain, hip pain and lower back pain.
  • The podiatrists and foot doctors at Advanced Foot and Ankle Specialists of Pinckney Michigan have developed a treatment algorithm for diagnosing and treating bunion pain with both surgery and without surgery.
  • All podiatrists foot doctors are on staff at St. Joseph Mercy hospitals in Ann Arbor, Howell and Brighton Michigan.

OSSIO Receives FDA 510(k) Clearance for OSSIOfiber® Hammertoe Fixation System

Retrieved on: 
Thursday, March 12, 2020
Medical devices, FDA, Health, Surgery, Clinical trials, Biotechnology, Medical specialties, Surgery, Medicine, Bone fractures, Arthropathies, Hammer toe, Orthopedic surgery, Bone fracture, Bone grafting, Bone, OSSIOfiber, OSSIO

OSSIO, Inc., an orthopedic fixation company, today announced that its OSSIOfiber Hammertoe Fixation System has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts.

Key Points: 
  • OSSIO, Inc., an orthopedic fixation company, today announced that its OSSIOfiber Hammertoe Fixation System has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts.
  • The OSSIOfiber Hammertoe Fixation System comprises the companys breakthrough OSSIOfiber Intelligent Bone Regeneration Technology, a new category of fixation material that combines unparalleled mechanical strength and natural bone healing in a non-permanent implant.
  • In 2019, OSSIO completed enrollment in its European multi-center clinical trial designed to assess the safety and performance of the OSSIOfiber Hammertoe Fixation System.
  • These findings will serve to support OSSIOs Conformit Europene (CE) Mark application for approval of the OSSIOfiber Hammertoe Fixation System later this year.

Paragon 28® launches sterile kit to streamline delivery of its transformational HammerTube™ Hammertoe System

Retrieved on: 
Wednesday, November 20, 2019
Musculoskeletal system, Prosthetics, Medical Subject Headings, Arthropathies, Hammer toe, Implant, Pip, Interphalangeal joints of the hand, SmartToe

Paragon 28 launched the HammerTube Hammertoe System in March 2018.

Key Points: 
  • Paragon 28 launched the HammerTube Hammertoe System in March 2018.
  • The HammerTube is a single piece titanium sprayed PEEK (Polyetheretherketone) implant intended for use in proximal interphalangeal (PIP) joint fusions.
  • The HammerTube implant system provides four unique implants in 2.75 mm and 3.50 mm straight and angled options.
  • The sterile launch is expected to greatly expand accessibility to this solution allowing clinicians and health care networks the most efficient and safe access to the HammerTube System.